Ken Griffin Tyme Technologies, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

Shares

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$0.23 - $0.35 $2,930 - $4,459	-12,741 Reduced 49.06%	13,228 $4,000
Q1 2022 May 16, 2022	BUY	$0.28 - $0.68 $2,033 - $4,937	7,261 Added 38.81%	25,969 $9,000
Q4 2021 Feb 14, 2022	SELL	$0.6 - $1.04 $28,617 - $49,602	-47,695 Reduced 71.83%	18,708 $11,000
Q3 2021 Nov 15, 2021	SELL	$0.99 - $1.38 $10,443 - $14,557	-10,549 Reduced 13.71%	66,403 $68,000
Q2 2021 Aug 16, 2021	SELL	$1.14 - $1.87 $51,812 - $84,991	-45,450 Reduced 37.13%	76,952 $96,000
Q1 2021 May 17, 2021	BUY	$1.34 - $3.53 $164,018 - $432,079	122,402 New	122,402 $218,000
Q3 2020 Nov 16, 2020	SELL	$0.93 - $1.35 $34,372 - $49,896	-36,960 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$0.97 - $1.7 $20,810 - $36,471	-21,454 Reduced 36.73%	36,960 $49,000
Q1 2020 May 15, 2020	BUY	$0.9 - $1.95 $24,073 - $52,158	26,748 Added 84.47%	58,414 $64,000
Q3 2019 Nov 14, 2019	BUY	$0.97 - $1.77 $30,716 - $56,048	31,666 New	31,666 $37,000
Q2 2019 Aug 14, 2019	SELL	$0.96 - $1.89 $9,813 - $19,319	-10,222 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$1.76 - $3.73 $17,990 - $38,128	10,222 New	10,222 $0

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.